ALK-Abelló A/S (CO:ALK-B) — Market Cap & Net Worth
Market Cap & Net Worth: ALK-Abelló A/S (ALK-B)
ALK-Abelló A/S (CO:ALK-B) has a market capitalization of $6.15 Billion (Dkr39.29 Billion) as of September 16, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #3136 globally and #20 in its home market, demonstrating a -6.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALK-Abelló A/S's stock price Dkr195.20 by its total outstanding shares 201305917 (201.31 Million). Also see ALK-Abelló A/S (ALK-B) total assets for a full breakdown of the balance sheet.
ALK-Abelló A/S Market Cap History: 2015 to 2026
ALK-Abelló A/S's market capitalization history from 2015 to 2026. Data shows growth from $1.37 Billion to $6.15 Billion (16.52% CAGR). Also see ALK-B cash flow metrics for how efficiently the company converts equity into cash flow.
ALK-Abelló A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALK-Abelló A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ALK-Abelló A/S (ALK-B) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.14x
ALK-Abelló A/S's market cap is 1.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.01x
ALK-Abelló A/S's market cap is 6.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.44 Billion | $3.00 Billion | $270.00 Million | 0.48x | 5.34x |
| 2017 | $1.17 Billion | $2.91 Billion | -$158.00 Million | 0.40x | N/A |
| 2018 | $1.51 Billion | $2.92 Billion | -$170.00 Million | 0.52x | N/A |
| 2019 | $2.57 Billion | $3.27 Billion | -$50.00 Million | 0.79x | N/A |
| 2020 | $3.94 Billion | $3.49 Billion | $25.00 Million | 1.13x | 157.48x |
| 2021 | $5.40 Billion | $3.92 Billion | $219.00 Million | 1.38x | 24.66x |
| 2022 | $3.03 Billion | $4.51 Billion | $335.00 Million | 0.67x | 9.03x |
| 2023 | $3.19 Billion | $4.82 Billion | $486.00 Million | 0.66x | 6.56x |
| 2024 | $5.01 Billion | $5.54 Billion | $815.00 Million | 0.90x | 6.15x |
| 2025 | $7.20 Billion | $6.31 Billion | $1.20 Billion | 1.14x | 6.01x |
Competitor Companies of ALK-B by Market Capitalization
Companies near ALK-Abelló A/S in the global market cap rankings as of September 16, 2026. Review ALK-B tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ALK-Abelló A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
ALK-Abelló A/S Historical Marketcap From 2015 to 2026
Between 2015 and today, ALK-Abelló A/S's market cap moved from $1.37 Billion to $ 6.15 Billion, with a yearly change of 16.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr6.15 Billion | -14.61% |
| 2025 | Dkr7.20 Billion | +43.68% |
| 2024 | Dkr5.01 Billion | +57.21% |
| 2023 | Dkr3.19 Billion | +5.36% |
| 2022 | Dkr3.03 Billion | -43.99% |
| 2021 | Dkr5.40 Billion | +37.20% |
| 2020 | Dkr3.94 Billion | +52.91% |
| 2019 | Dkr2.57 Billion | +70.31% |
| 2018 | Dkr1.51 Billion | +29.73% |
| 2017 | Dkr1.17 Billion | -19.14% |
| 2016 | Dkr1.44 Billion | +5.57% |
| 2015 | Dkr1.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of ALK-Abelló A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.15 Billion USD |
| MoneyControl | $6.15 Billion USD |
| MarketWatch | $6.15 Billion USD |
| marketcap.company | $6.15 Billion USD |
| Reuters | $6.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more